Advice
Following a resubmission.
Rasagiline (Azilect) is not recommended within NHS Scotland for the treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Rasagiline reduces off-time in patients with Parkinson’s disease and end of dose fluctuations on levodopa, similar to reductions shown with the less effective of two currently marketed catechol-O-methyl transferase inhibitors. The economic case has not been demonstrated.
Download detailed advice41KB (PDF)
Medicine details
- Medicine name:
- rasagiline 1mg (Azilect)
- SMC ID:
- 255/06
- Indication:
- Treatment of ideopathic Parkinson' s Disease
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 11 December 2006